Morpholine

Morpholine

SCHEMBL21359321

C1COCCN1.CCCOc1ccccc1-c1ccccc1

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.50
ADRB2 P07550 3/20 0.50
ALDH1A1 P00352 4/20 0.49
TDP1 Q9NUW8 1/20 0.49
USP2 O75604 1/20 0.49
HTR7 P34969 1/20 0.49
TP53 P04637 1/20 0.48
MAPK1 P28482 1/20 0.48
RAB9A P51151 1/20 0.48
POLB P06746 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
HRH1 P35367 1/20 0.46
ADRB1 P08588 1/20 0.45
KMT2A Q03164 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MEN1 O00255 1/20 0.43
HTT P42858 2/20 0.43
LMNA P02545 1/20 0.43
MAOA P21397 1/20 0.43
ADRA1D P25100 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1389258 0.83 ADRB2 (0.67) KDM4EADRB2ALDH1A1HTR7TP53
Water SCHEMBL27583143 0.82 ADRB2 (0.65) KDM4EADRB2ALDH1A1HTR7TP53
SCHEMBL27301114 0.80 ADRB2 (0.63) KDM4EADRB2ALDH1A1HTR7TP53
SCHEMBL10706756 0.75 ADRB2 (0.65) KDM4EADRB2ALDH1A1HTR7TP53
SCHEMBL4724735 0.75 PDE5A (0.40) KDM4EADRB2ALDH1A1USP2TP53
SCHEMBL28311408 0.74 KDM4E (0.75) KDM4EALDH1A1TDP1HTR7TP53
SCHEMBL7638760 0.74 ADRB2 (0.63) KDM4EADRB2ALDH1A1HTR7TP53
SCHEMBL34465293 0.74 ADRB2 (0.63) KDM4EADRB2ALDH1A1HTR7TP53
SCHEMBL27528318 0.73 ADRB2 (0.54) KDM4EADRB2ALDH1A1HTR7TP53
SCHEMBL10438816 0.73 HTR7 (0.53) KDM4EADRB2ALDH1A1USP2HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11999723-B2 Pyrazole-containing macrophage migration inhibitory factor inhibitors YALE UNIVERSITY (US) 2024-06-04 US claimed
US-20230057076-A1 Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors UNIV YALE (US) 2023-02-23 US claimed
US-20210002264-A1 Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors UNIV YALE (US) 2021-01-07 US claimed
WO-2019178480-A1 PYRAZOLE-CONTAINING MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS YALE UNIVERSITY (US) 2019-09-19 WO claimed
US-11999723-B2 Pyrazole-containing macrophage migration inhibitory factor inhibitors YALE UNIVERSITY (US) 2024-06-04 US disclosed
US-20230057076-A1 Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors UNIV YALE (US) 2023-02-23 US disclosed
US-20210002264-A1 Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors UNIV YALE (US) 2021-01-07 US disclosed
WO-2019178480-A1 PYRAZOLE-CONTAINING MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS YALE UNIVERSITY (US) 2019-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11999723-B2 Pyrazole-containing macrophage migration inhibitory factor inhibitors MIF, MMP12, CSF1R KDM4E 1525/4885ADRB2 3915/4885ALDH1A1 2824/4885
US-20210002264-A1 Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors MIF, MMP12, CSF1R KDM4E 1211/4885ADRB2 3915/4885ALDH1A1 2891/4885
US-20230057076-A1 Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors MIF, MMP12, CSF1R KDM4E 1525/4885ADRB2 3915/4885ALDH1A1 2824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.